CD163 and mycosis fungoides: Treatment with an anti-CCR4 monoclonal antibody (mogamulizumab) has been shown to induce a characteristic immunologic signature in more than 25% of patients with MF and SS, including increased expression of CD7, CD8, and CD163+ M2-polarized macrophages [35,36].